Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects (UV)
Viral Infection
About this trial
This is an interventional treatment trial for Viral Infection focused on measuring Dengue, Arbovirus Infections, Flaviviridae Infections, Flavivirus Infections, Hemorrhagic Fevers, Viral, RNA Virus Infections, Virus Diseases, Pharmaceutical Solutions, Pharmacologic Actions, Therapeutic Uses
Eligibility Criteria
Inclusion Criteria:
- Healthy subjects
- Women: non-pregnant, non-lactating; if of childbearing potential, on specified contraception measures during the study period
- Men: using barrier contraception measures during the study period
Exclusion Criteria:
- Health conditions
- Taking prescription and non-prescription drugs (exceptions: acetaminophen, vitamins, hormonal birth control)
Sites / Locations
- Quintiles, Inc
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Cohort 1 - 3 mg UV-4B
Cohort 2 - 10 mg UV-4B
Cohort 3- 30 mg UV-4B
Cohort 4 - 90 mg UV-4B
Cohort 5 - 180 mg UV-4B
Cohort 6 - 360 mg UV-4B
Cohort 7 - 720 mg UV-4B
Cohort 8 - 1000 mg UV-4B
Subjects receiving UV-4B 3 mg oral solution or placebo
Subjects receiving UV-4B 10 mg oral solution or placebo
Subjects receiving UV-4B 30 mg oral solution or placebo
Subjects receiving UV-4B 90 mg oral solution or placebo
Subjects receiving UV-4B 180 mg oral solution or placebo
Subjects receiving UV-4B 360 mg oral solution or placebo
Subjects receiving UV-4B 720 mg oral solution or placebo
Subjects receiving UV-4B 1000 mg oral solution or placebo